Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension of ibrutinib in older patients with CLL/SLL from PCYC-1115-CA
2012-003968-44Phase 3Completed
- Sponsor
- Pharmacyclics
- Start
- Nov 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of ibrutinib in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and B-cell prolymphocytic leukemia (B-PLL), sponsored by Pharmacyclics. Primary endpoint: Progression-free survival on first-line therapy. Started Nov 2012; status: completed.
02
Drugs
ibrutinib
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)B-cell prolymphocytic leukemia (B-PLL)
Beyond the preview
Go deeper on 2012-003968-44.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-003968-44.